RxDoctor Payments Data

Maria Velazquez Lamela, MD

Glaucoma Specialist · Caguas, PRNPI 1578907614

Payments from drug & device makers

$9,960in general payments, 2019–2025

Across 69 payments — averaging $144.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • NEW World Medical,inc.$720
  • Mallinckrodt Hospital Products Inc.$331
  • Bausch & Lomb Americas Inc.$320
  • Alcon Puerto Rico Inc$259
  • Alcon$237
  • plus $856 from 8 others

What the payments were for

  • Speaking & faculty fees$6,17562%
  • Food & beverage$3,66237%
  • Education$1231%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$29,959
Medicare patients
45
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost2,536$735,139
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol806$137,829
CombiganBrimonidine Tartrate/Timolol498$118,595
RestasisCyclosporine141$92,117
Prednisolone Acetate1,328$86,876
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat2,197$73,368
Alphagan PBrimonidine Tartrate281$66,678
Brimonidine Tartrate1,444$55,757
AzoptBrinzolamide116$45,400
SimbrinzaBrinzolamide/Brimonidine Tart213$44,966
Latanoprost2,674$33,068
XiidraLifitegrast36$25,532
Dorzolamide Hcl767$21,954
Cyclosporine87$20,759
VyzultaLatanoprostene Bunod65$18,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$7,237$1,012,5293,456 claims
AlconAzopt, Simbrinza$237$90,366329 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$320$43,822101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Caguas

Where these figures come from

Is this you, or does something look wrong? →